Medtronic wins expanded indication for sinus dilation balloon

fusion
The Fusion navigation system--Courtesy of Medtronic

The FDA expanded the indication for Medtronic’s ($MDT) NuVent sinus dilation balloon to include patients with scarred, granulated or previously surgically altered tissue.

The device is currently the only balloon sinus dilation system on the market with built-in electromagnetic surgical navigation that helps surgeons confirm sinus anatomy and place the balloon during surgery. It uses an image guidance technology called Fusion, which displays a “map” of the sinus anatomy, helping physicians precisely target points in blocked sinuses for dilation during minimally invasive surgery.

The expanded indication is based on a prospective, nonrandomized, nonblinded, single-arm study conducted at multiple sites in the U.S. According to the CDC, 29.4 million adults have diagnosed sinusitis in the U.S. While the bulk of these cases are treated with antibiotics, decongestants and saline sprays, some patients must undergo sinus surgery to find relief.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Medtronic launched NuVent in August 2014 for sinus surgery. The new clearance will make the NuVent system an option for patients who need revision sinus surgery. Revision surgery is required by patients for whom the initial sinus surgery did not work. It can be challenging due to scar tissue and differences in anatomy caused by previous surgeries.

"[NuVent] has been extraordinarily useful in accomplishing the goals of revision functional endoscopic sinus surgery, particularly to address technical challenges associated with the frontal sinus,” said Dr. Rick Chandra, professor of otolaryngology at Vanderbilt University, in the statement.

- here's the statement

Related Articles:
Medtronic says it is 'two to three years' ahead of competition on artificial pancreas
Medtronic buys into power morcellators in $350M purchase from Smith & Nephew
Medtronic slides into hearing devices with magnetic implant startup acquisition
Medtronic launches biofragmentable, injectable nasal packing and stent for sinus surgery

Read more on

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.